miR-149-3p suppressed epithelial–mesenchymal transition and tumor development in acute myeloid leukemia

References

• Chung C, Ma H. Driving toward precision medicine for acute leukemias: are we there Yet? Pharmacotherapy. 2017;37(9):1052–1072.
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051–1062.
   PubMed Web of Science ®Google Scholar
• Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894–1907.
   PubMed Web of Science ®Google Scholar
• Shipley JLandButera JN. Acute myelogenous leukemia. Exp Hematol. 2009;37(6):649–658.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
   PubMed Web of Science ®Google Scholar
• IandAbdul-Hay M DK. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441.
   PubMedGoogle Scholar
• Tamamyan G, Kadia T, Ravandi F, et al. Frontline treatment of acute myeloid leukemia in adults. Crit Rev Oncol Hematol. 2017;110:20–34.
   PubMed Web of Science ®Google Scholar
• Nanbakhsh A, Visentin G, Olive D, et al. miR-181a modulates acute myeloid leukemia susceptibility to natural killer cells. Oncoimmunology. 2015;4(12):e996475.
   PubMed Web of Science ®Google Scholar
• Zhou J, Ching YQ, Chng WJ. Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target. Oncotarget. 2015;6(8):5490–5500.
   PubMed Web of Science ®Google Scholar
• Rautenberg C, Germing U, Haas R, et al. Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: prevention, detection, and treatment. Int J Mol Sci. 2019;20(1):228.
   Web of Science ®Google Scholar
• Hackl H, Astanina K, Wieser R. Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia. J Hematol Oncol. 2017;10(1):51.
   PubMedGoogle Scholar
• Zhou J, Goh BC, Albert DH, et al. ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J Hematol Oncol. 2009;2:33.
   PubMed Web of Science ®Google Scholar
• Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141(4):1202–1207.
   PubMed Web of Science ®Google Scholar
• Croce CMandCalin GA. miRNAs, cancer, and stem cell division. Cell. 2005;122(1):6–7.
   PubMed Web of Science ®Google Scholar
• White NM, Fatoohi E, Metias M, et al. Metastamirs: a stepping stone towards improved cancer management. Nat Rev Clin Oncol. 2011;8(2):75–84.
   PubMed Web of Science ®Google Scholar
• Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–469.
   PubMed Web of Science ®Google Scholar
• Mardani R, Jafari Najaf Abadi MH, Motieian M, et al. MicroRNA in leukemia: tumor suppressors and oncogenes with prognostic potential. J Cell Physiol. 2019;234(6):8465–8486.
   PubMed Web of Science ®Google Scholar
• Fernandes Q. MicroRNA: defining a new niche in leukemia. Blood Rev. 2017;31(3):129–138.
   PubMed Web of Science ®Google Scholar
• Vandewalle V, Essaghir A, Bollaert E, et al. miR-15a-5p and miR-21-5p contribute to chemoresistance in cytogenetically normal acute myeloid leukaemia by targeting PDCD4, ARL2 and BTG2. J Cell Mol Med. 2020;25(1):575–585.
   PubMed Web of Science ®Google Scholar
• Chen X, Guo Z, Fan S, et al. Integrating microRNA and mRNA expression in rapamycin-treated T-cell acute lymphoblastic leukemia. Pathol Res Pract. 2019;215(8):152494.
   PubMed Web of Science ®Google Scholar
• Huang M, Huang Y, Guo J, et al. Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable threonine tyrosine kinase (TTK) inhibitors. Eur J Med Chem. 2020;211:113023.
   PubMed Web of Science ®Google Scholar
• Menon SS, Guruvayoorappan C, Sakthivel KM, et al. Ki-67 protein as a tumour proliferation marker. Clin Chim Acta. 2019;491:39–45.
   PubMed Web of Science ®Google Scholar
• Yang D, Du G, Xu A, et al. Expression of miR-149-3p inhibits proliferation, migration, and invasion of bladder cancer by targeting S100A4. Am J Cancer Res. 2017;7(11):2209–2219.
   PubMed Web of Science ®Google Scholar
• Si L, Xu L, Yin L, et al. Potent effects of dioscin against pancreatic cancer via miR-149-3P-mediated inhibition of the Akt1 signalling pathway. Br J Pharmacol. 2017;174(7):553–568.
   PubMed Web of Science ®Google Scholar
• Cao D, Jia Z, You L, et al. 18beta-glycyrrhetinic acid suppresses gastric cancer by activation of miR-149-3p-Wnt-1 signaling. Oncotarget. 2016;7(44):71960–71973.
   PubMedGoogle Scholar
• Yao J, Wu X. Upregulation Of miR-149-3p suppresses spinal chordoma malignancy by targeting Smad3. Onco Targets Ther. 2019;12:9987–9997.
   PubMed Web of Science ®Google Scholar
• Okato A, Arai T, Yamada Y, et al. Dual strands of pre-miR-149 inhibit cancer cell migration and invasion through targeting FOXM1 in renal cell carcinoma. Int J Mol Sci. 2017;18(9):1969.
   PubMed Web of Science ®Google Scholar
• Carmona-Gutierrez D, Eisenberg T, Buttner S, et al. Apoptosis in yeast: triggers, pathways, subroutines. Cell Death Differ. 2010;17(5):763–773.
   PubMed Web of Science ®Google Scholar
• Wang L, Ma G, Zhang Y, et al. Effect of mitochondrial cytochrome c release and its redox state on the mitochondrial-dependent apoptotic cascade reaction and tenderization of yak meat during postmortem aging. Food Res Int. 2018;111:488–497.
   PubMed Web of Science ®Google Scholar
• Adachi S, Cross AR, Babior BM, et al. Bcl-2 and the outer mitochondrial membrane in the inactivation of cytochrome c during Fas-mediated apoptosis. J Biol Chem. 1997;272(35):21878–21882.
   PubMed Web of Science ®Google Scholar
• Chen D, Zhang M, Ruan J, et al. The long non-coding RNA HOXA11-AS promotes epithelial mesenchymal transition by sponging miR-149-3p in colorectal cancer. J Cancer. 2020;11(20):6050–6058.
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196.
   PubMed Web of Science ®Google Scholar
• Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69–84.
   PubMed Web of Science ®Google Scholar
• Wu S, Du Y, Beckford J, et al. Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukemia. J Transl Med. 2018;16(1):170.
   PubMedGoogle Scholar
• Zhang TJ, Zhou JD, Ma JC, et al. CDH1 (E-cadherin) expression independently affects clinical outcome in acute myeloid leukemia with normal cytogenetics. Clin Chem Lab Med. 2017;55(1):123–131.
   PubMed Web of Science ®Google Scholar